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INTRODUCTION
Helicobacter pylori (H. pylori) is a spiral Gram-negative
bacterium with a relatively small genome (~1.65 Mb),
and is known to be the most common human bacterial
infection worldwide, infecting about half of the
world’s population. There is now much evidence that
H. pylori and related Helicobacter species have been part
of  the normal microbiota of  humans and our
ancestors for millions, if not tens of millions, of years
or longer.1,2
The prevalence of Helicobacter pylori infection varies
greatly among countries and among population groups
within the same country, but is falling in most
developed countries3. In the last 30 years, since H. pylori
was first described and cultured, a complete paradigm
shift has occurred in the clinical approach to the
diagnosis and treatment of upper gastro-duodenal
disease. Peptic ulcer disease is now approached as an
infectious disease, in which elimination of the causative
agent cures the condition. The role of H. pylori infection
in gastric cancers is increasingly recognized, and its role
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Helicobacter pylori is a spiral Gram-negative bacterium with a relatively
small genome and is known to be the most common human bacterial
infection worldwide, infecting about half of the world’s population.
The bacterium represents one of the most successful human pathogens,
inducing severe clinical symptoms only in a small subset of individuals,
thus signifying a highly balanced degree of co-evolution of H. pylori
and humans. The prevalence of Helicobacter pylori infection varies
greatly among countries and among population groups within the same
country, but is falling in most developed countries. The clinical course
of H. pylori infection is highly variable and is influenced by both
microbial and host factors including genetic susceptibility while the
pattern and distribution of  inflammation correlate strongly with the
risk of clinical sequelae, namely duodenal or gastric ulcers, mucosal
atrophy, gastric carcinoma, or gastric lymphoma. Cytokine gene
polymorphisms directly influence inter-individual variation in the
magnitude of cytokine response, and this clearly contributes to an
individual’s ultimate clinical outcome. Polymorphisms in genes coding
for innate immune factors have also been incriminated in the pathogenesis
of H. pylori related disease, while promoter hypermethylation of  tumor
suppressor genes is considered an important factor in carcinogenesis
and known to be present in H. pylori associated gastric tumors.
Functional genomics may fill many of the gaps in our understanding of
the pathogenesis of H. pylori infection and accelerate the development
of novel therapies, including H. pylori specific antimicrobial agents.
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in other diseases of the upper gastrointestinal tract is
being evaluated. Effective antimicrobial therapy is
available, although there is still no ideal treatment, and
indications for therapy continue to evolve.
Helicobacter pylori infection is usually acquired early in
childhood but infection persists lifelong in the absence
of treatment, and the majority (80%–90%) of those
infected will carry and transmit H. pylori without any
symptoms of disease. All strains cause gastric
inflammation, however, only 15% of infections result
in peptic ulceration and only 0.5%–2% in gastric
adenocarcinoma.4 In some subjects, H. pylori is
considered as a commensal and not a pathogen, making
it difficult to determine who should be treated to
prevent serious sequelae.5 Many clinical and basic
research studies have been undertaken to define what
makes H. pylori a pathogen.  The clinical course of H.
pylori infection is highly variable and is influenced by
both microbial and host factors including genetic
susceptibility. The pattern and distribution of
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inflammation correlate strongly with the risk of clinical
sequelae, namely duodenal or gastric ulcers, mucosal
atrophy, gastric carcinoma, or gastric lymphoma.
There has been recent interest in whether H. pylori may
cause or be a risk factor for human diseases outside
the upper gastrointestinal tract. These include idiopathic
thrombocytopenic purpura, various skin diseases, liver
diseases, cardiovascular and cerebrovascular disease.6
This review highlights recent advances in the
understanding of   genetic determinants of Helicobacter
pylori infection as well as the interplay of clinical and
morphological patterns in disease manifestation.
Natural History of Helicobacter Pylori Infection
H. pylori is a gram-negative bacterium, measuring 2 to
4 µm in length and 0.5 to 1 µm in width. Although
usually spiral-shaped, the bacterium can appear as a
rod, while coccoid shapes appear after prolonged in
vitro culture or antibiotic treatment. Colonization
typically occurs during childhood and persists for the
lifetime of the host in the absence of treatment, and
such persistence within the context of ongoing gastric
inflammation is the signature feature of H. pylori
infection8.
Whether childhood colonization causes symptoms or
changes in gastric acidity is unknown, however, H. pylori
persistence is central to pathogenesis. Primary
acquisition in adults, or reinfection after successful
eradication, does occur but is less common, with an
annual incidence of 0.3­0.7% in developed countries
and 6­14% in developing countries.9 It has been
suggested that the age when H. pylori is acquired is an
important determinant of  the ultimate risk for diseases,
such as PUD and noncardia gastric cancer.10 This
hypothesis is also based on changes in the equilibria
reached between microbial populations and hosts and
is consistent with acquisition age outcome differences
observed for other microbial agents (e.g., varicella,
hepatitis B, and Epstein-Barr viruses).11 In the rare cases
where colonization first occurs in adults, it can cause a
profound gastritis with hypochlohydria, epigastric
discomfort, and nausea.12,13 Ulcers occur mainly in mid-
or late adulthood after many years of infection and
inflammation, and gastric adenocarcinoma occurs in
late adulthood after an even longer period of chronic
inflammation and epithelial damage.
Transmission
The very large number of people colonized throughout
the world suggest that H. pylori evolved a very robust
strategy of  transmission. Unlike many organisms that
have free-living forms in environmental reservoirs and
unlike those that can infect many different animal and
plant species, natural H. pylori infection is restricted to
humans and closely related primates. Epidemiologic
studies of H. pylori transmission show that the majority
of infections tend to occur within families through
close person-to-person contact.14
Most H. pylori transmission occurs in childhood, and,
in some countries, up to 90% of children become
infected by age 10 years, with reports of infection as
early as the first months of life.15 Maternal-to-child
and sibling-sibling transmission seem most likely
because longitudinal studies have shown that the risk
of acquiring the infection is highly correlated to the
infection status of the mother16 and siblings17  and
related to overcrowding conditions in the home.18
It seems likely that in industrialized countries direct
transmission from person to person by vomitus, saliva,
or feces predominates; additional transmission routes,
such as water, may be important in developing
countries.19,20 There is currently no evidence for
zoonotic transmission, although H. pylori is found in
some non-human primates and occasionally in other
animals21,22
Some investigators propose that H. pylori may exist in
the environment in a dormant, spore-like state that
can be viable but non-cultivable. This hypothesis partially
comes from the observation that, under stress and
nutrient deprivation, H. pylori undergoes a morphologic
transformation from actively dividing and swimming
spiral bacilli to inactive cocci. However, until now, no
definitive experimental evidence exists that H. pylori
can revert from a coccoid form into the infectious
spiral bacilli. In contrast, there is ample experimental
evidence that culturable bacilli are infectious in animal
models, in volunteer studies,23 and in reports of
inadvertent transmission through contaminated
endoscopes.24
It seems more likely that transmission occurs when H.
pylori is present outside of the stomach in a culturable
form. However, it is known that H. pylori is fragile
outside of the human stomach because it is rapidly
killed by higher oxygen tension and even by light.25
The most likely modes of transmission seem to be
situations in which gastric contents can be transferred
quickly from person to person. Gastric-oral
transmission is suggested in association with
gastroenteritis with vomiting. Oral-oral transmission
is also possible if H. pylori can survive for short periods
after gastric contents have refluxed into the oral cavity.
Fecal-oral transmission may be possible under
conditions in which H. pylori survive transit through
the lower gastrointestinal tract, which is uncommon in
healthy people.26–29 An aspect of transmission specific
H. pylori factors that has received attention and debate
                                                   Annals of Ibadan Postgraduate  Medicine. Vol. 12 No. 1 June, 2014              23
is whether the coccoid form of H. pylori is viable or
simply a form of  bacterial death. A recent report found
that the H. pylori cell wall enzyme AmiA, a
peptidoglycan hydrolase, is involved in the
morphologic transition from spiral to coccoid,
suggesting that the coccoid transition might be a
regulated process rather than a degenerate form of
H. pylori.30 Interestingly, this study30 showed that the
peptidoglycan of  the coccoid form is a poor activator
of  the innate immune response, and the authors suggest
that the transition into coccoid may represent
remodeling of the cell wall for the purpose of immune
modulation. Nagai et al recently observed that the
coccoid form of H. pylori is phagocytosed by dendritic
cells in Peyer’s patches.31 They proposed that H. pylori
converts to the coccoid form in the anaerobic small
intestine and stimulates the host immune system through
Peyer’s patches. Although the speculation that the
coccoid form of H. pylori may act to protect the rest
of the population from immune attack remains to be
tested, the notion that H. pylori exists in many forms
that are dynamic and adapt to changing conditions in
the gastric mucosa is a recurrent theme in H. pylori
biology.14
Host Genetic Factors in H. pylori-Induced
Disease
The interactions between H. pylori virulence
determinants and host epithelial cells induce genetic,
epigenetic and chromosomal alterations in the host
genetic material. It results in a continuous patching of
the genetic information of  the host cells, which favours
the development of gastric carcinoma.
Cytokine gene polymorphisms directly influence inter-
individual variation in the magnitude of cytokine
response, and this clearly contributes to an individual’s
ultimate clinical outcome (Table 1). Specific
polymorphisms in the IL-1B gene and the IL-1
receptor-antagonist gene (IL-1RN) lead to increased
gastric mucosal levels of IL-1â in individuals infected
with H. pylori32  and increased levels of inflammation.33
The polymorphisms also increase the risk of gastric
atrophy, achlorhydria, intestinal metaplasia,34 and distal
gastric adenocarcinoma.35 Individuals with the IL-1B-
31*C or -511*T and IL-1RN*2/*2 genotypes have
been found to be  at increased  risk of developing
hypochlorhydria and gastric atrophy in response to
H. pylori infection as well as a 2- to 3-fold increased
risk of malignancy compared with subjects who have
the less pro-inflammatory genotypes**.36, 37 IL-1 is also
the most powerful acid inhibitor known.38 The effect
of these polymorphisms on duodenal ulcer risk is
uncertain; one report showed an increased risk with
pro-inflammatory polymorphisms,39 but another
showed a reduced risk.34 Furthermore, the pro-
inflammatory IL-1 genotypes increased the risk of both
intestinal and diffuse types of gastric cancer, but the
risk was restricted to the non-cardia subsite.
Figueiredo et al40 reported on the combined effects
of pro-inflammatory IL-1 genotypes and H. pylori
bacterial virulence factors (cagA positive, VacA s1, and
VacA m1). They showed that, for each combination
of bacterial/host genotype, the odds of having gastric
carcinoma were greatest in those with both bacterial
and host high-risk genotypes, having  up to fifty-fold
increased risk of gastric cancer as compared with
individuals lacking these factors. This highlights the
important interaction between host and bacterium in
the pathogenesis of  gastric cancer. Although
polymorphisms affecting IL-1 levels are best studied,
others also appear important.
Tumor necrosis factor (TNFA) polymorphisms have
not been demonstrated to affect gastric mucosal levels
of TNF, but they have been shown to affect gastric
inflammation and cancer risk in some39 but not all
studies (Table 1).41 Carriage of  the pro-inflammatory
A allele of TNF-A-308 G A polymorphism
increased the odds ratio for non-cardia gastric cancer
to 2.2 (95% CI: 1.4 –3.7). IL-10 is an anti-inflammatory
cytokine with opposing actions to IL-1, TNF,
interferon-, and other pro-inflammatory cytokines.
Relative deficiency of IL-10 may result in a Th-1-driven
hyper-inflammatory response to H. pylori with greater
damage to the gastric mucosa.  Homozygosity for the
low-IL-10 A-T-A haplotype (based on 3 promoter
polymorphisms at positions -592, -819, and -1082)
increased the risk of non-cardia gastric cancer with an
odds  ratio of 2.5 (95% CI: 1.1–5.7)37. Another
important cytokine that plays a central role in the
pathogenesis of H. pylori-induced diseases is IL-8. This
chemokine belongs to the CXC family and is a potent
chemoattractant for neutrophils and lymphocytes. It
also has effects on cell proliferation, migration, and
tumor angiogenesis. The gene has a well-established
promoter polymorphism at position -251 (IL-8-251
TA). The A allele is associated with increased
production of IL-8 in H. pylori-infected gastric mucosa.
It was also found to increase the risk of severe
inflammation and precancerous gastric abnormalities
in white42 and Asian populations.43
Polymorphisms in genes coding for innate immune
factors have also been incriminated in the pathogenesis
of H. pylori related disease. An example is the functional
polymorphism at position -896 in exon 4 of  the Toll-
like receptor-4 (TLR4) gene. TLR4, the lipopolysacch-
aride (LPS) receptor, was initially identified as the
potential signaling receptor for H. pylori on gastric
epithelial cells. ***Amieva & El-Omar14 proposed that
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subjects with an overall pro-inflammatory genetic
makeup based on a combination of markers from
the adaptive and innate immune systems (eg, IL-1,
TNF, IL-10, IL-8, TLR4, mannose-binding lectin170)
respond to H. pylori infection by creating an
environment within the stomach that is chronically
inflamed and with reduced acidity.
Several studies have also examined the role of HLA
class I and II alleles in gastric cancer, in white and non-
white populations. Lee et al found that the HLA class
II allele DQB1*0301 was more common in white
patients with gastric adenocarcinoma than non-cancer
controls.44
Epigenetic changes: Promoter hypermethylation of
tumor suppressor genes is considered an important
factor in carcinogenesis and known to be present in
H. pylori associated gastric tumors.
Shin et al 45 showed that this aberrant methylation is
already present in the premalignant stages of gastric
status of a series of miRs in a series of gastric cancer
cell lines, in primary gastric cancers, and in gastric
mucosa from patients with or without H. pylori
infection, and provided evidence that H. pylori infection
is associated with higher methylation of miR-124. In
vitro experiments with overexpression or  silencing
of miR-218 allowed Gao et al48 to demonstrate that
miR-218 induces apoptosis and decreases cell
proliferation by promoting ECOP (epidermal growth
factor receptor coamplified and overexpressed
protein) degradation, which decreases NF-kB
activation. Interference with these miR methylations
might provide novel options for fighting gastric cancer
development in H. pylori-infected patients.
The Clinical Outcomes of Infection
The clinical course of H. pylori infection is highly
variable and is influenced by both microbial and host
factors. The basic process that mediates H. pylori-
induced damage is gastritis with its associated humoral
Polymorphism site Effect Association with H. pylori infection
IL-1B gene cluster IL-1B*-511T, IL-1B*-31C, & IL-




atrophic gastritis & gastric cancer
IL-8 (-251A/T)  expression of IL-8  risk of gastric cancer & peptic ulcer
IL-10 (ATA/GCC
haplotypes)
GCC haplotype results in 
expression of IL-10
GCC assoc. with Colonization by more-
virulent strains (cagA, vacA s1, and
babA2); ATA  risk of gastric cancer
TNF-A*-308A allele TNF- expression and
 gastrin expression
higher levels of H. pylori infection &
 risk of gastric cancer
Table 1: Genetic polymorphisms and H. pylori infection
cancer. Work by Schneider et al46 showed that the
degree of aberrant methylation is associated with the
presence/absence of known virulence factors in the
infecting H. pylori strain. Of particular interest are the
results regarding LOX, HAND1, THBD, p41ARC,
and APC promoter methylation, which were described
by Shin et al.45 In active H. pylori infection and  intestinal
metaplasia, there was hypermethylation involving the
LOX, HAND1, THBD, and APC genes. And this
hypermethylation state persisted in LOX, HAND1,
THBD, p41ARC in cases with past H pylori infection.
Among the epigenetic alterations following H. pylori
infection, deregulation of microRNAs (miRs)
expression might also be relevant for pathogenesis.
miRs are non-coding small RNAs which control
mRNA translation and they frequently are deregulated
in human cancers. Ando et al47 studied the methylation
and cell mediated immune mechanisms. The pattern
and distribution of gastritis correlate strongly with the
risk of clinical sequelae, namely duodenal or gastric
ulcers, mucosal atrophy, gastric carcinoma, or primary
gastric lymphoma (Figure 1).
In 2008, Amieva & El-Omar 14 proposed that three
main gastric phenotypes have been identified, and each
is associated with a set of pathophysiologic
abnormalities that could explain why a certain outcome
occurs. The commonest phenotype termed the “simple
or benign gastritis” phenotype, is characterized by mild
pan-gastritis with little disruption of gastric acid
secretion. This phenotype is commonly seen in subjects
who are asymptomatic and who on the whole develop
no serious gastrointestinal (GI) disease. The second
phenotype is the so-called duodenal ulcer (DU) phenotype
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and accounts for 10- 15% of infected subjects,
particularly in Western countries where peptic ulcers
were common. This phenotype is characterized by an
antral-predominant pattern of gastritis with relative
sparing of the acid producing corpus mucosa. Subjects
with this phenotype have high antral inflammatory
scores, high gastrin, relatively healthy corpus mucosa,
and very high acid output.49 H.pylori–induced hyper-
gastrinemia leads to an increased maximal acid output,
which indicates an increased parietal cell mass.These
subjects also have defective inhibitory control of gastric
acid secretion. Gastric hyperchlorhydria leads to an
increased acid load in the duodenum which
subsequently develops protective gastric metaplasia. H.
pylori colonizes this gastric metaplastic tissue, and the
resulting local inflammation and damage further
predispose to DU. The epidemiology of  pre-pyloric
and pyloric ulceration is similar to that of  DU, but
that of H. pylori–induced ulceration elsewhere in the
stomach is more similar to that of gastric
adenocarcinoma. The third and most serious
phenotype is the “gastric cancer phenotype,” which is
characterized by a pan-gastritis or a corpus-
predominant pattern of gastritis, multifocal gastric
atrophy, and hypo- or achlorhydria despite hyper
gastrinaemia.50 These abnormalities, which affect
approximately 1% of infected subjects, develop as a
direct result of the chronic inflammation induced by
the infection and increase the risk of  gastric cancer.51, 52
However, H. pylori treatment increases acid production
rapidly in some people with pan-gastritis and
hypochlorhydria (although not usually to normal levels)
53. This result implies a direct suppressive effect of H.
pylori–induced inflammatory mediators or products
such as IL-1, TNF, and, in a recent report, the Th-
1 cytokines IFN- and IL-1254 which all suppress acid
production. The gastric cancer phenotype is particularly
prevalent in certain parts of Asia, where this cancer is
common.55 Physiologically, the phenotype is
characterized by low acid secretion, high gastrin, and
low pepsinogen I and pepsinogen I/II ratio.
Carcinogenesis in the environment of gastric atrophy
is likely owing to reactive oxygen and nitrogen species
secondary to the accompanying inflammation, and
possibly partly caused by overgrowth of other bacteria
in the now achlorhydric  stomach. Other mechanisms
of carcinogenesis have also been either demonstrated
or implied in the atrophic stomach. Parietal cells express
the Sonic hedgehog protein, which is the main organizer
of  cell polarity in gastric pits. Sonic hedgehog
expression is lost in atrophy and intestinal metaplasia.56
The resultant disruption of parietal cell mass potentially
exposes stem cells to mutagenic agents.
Recent reports suggest that H. pylori may survive and
express virulence factors intracellularly in metaplastic,
dysplastic, and neoplastic epithelial cells in vivo, although
these reports need further confirmation. However,
several potential mechanisms exist for the proposed
direct oncogenic effects of H. pylori. CagA signaling is
strongly pro-proliferative. Also the pro-apoptotic
effects of H. pylori exhibited through NFB activation,
reduction in p27 levels, and down-regulation of the
TNF-related apoptosis-inducing ligand (TRAIL)
system contribute to the development of atrophic
gastritis a precancerous change. Other direct effects
of H. pylori on gastric epithelial cells that have potential
carcinogenic importance are its stimulation of reactive
oxygen species (ROS) and oxidative damage and its
impairment of  DNA mismatch repair.
 The most intriguing aspect of this story is that subjects
who develop duodenal ulcers are actually protected
from developing gastric cancer, suggesting that the 2
outcomes are mutually exclusive.
Gastric Ulceration (GU), unlike DU, is associated
with a pan-gastritic inflammation pattern and reduced
or normal acid production. GU’s arise most
commonly at the transitional zone between antrum
Fig. 1: (A) Chronic gastritis with florid mucosal infiltrates of  chronic inflammatory cells, (B) Gastric adenocarcinoma-
intestinal type, (C) Gastric MALT lymphoma with characteristic lymphoepithelial lesions (arrow).
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and corpus on the lesser gastric curve. It is likely that
the heavy colonization and consequent marked
inflammation and epithelial damage at this site lead
directly to ulceration. Why H. pylori–induced
inflammation has a pan-gastritic or corpus-
predominant pattern in some people when it is antral-
predominant in others is unknown. One possibility is
that, like autoimmune gastritis, it may be caused by
immune effectors with specificity for the gastric proton
pump ATPase.4
Primary Gastric Lymphoma
The acquisition of Mucosa-associated lymphoid tissue
(MALT), depends upon infection with helicobacter
species, usually H. pylori. Low-grade MALT
lymphomas do usually arise in the context of a pan-
gastritic inflammation pattern. In vitro, proliferation
of clonal B cells is driven by the presence of non-
neoplastic T cells, whose effects in turn are dependent
upon the presence of H. pylori. H. pylori also appears
to act through direct antigen stimulation of  tumor cells.
In humans, eradication of H. pylori frequently leads to
regression of  these low-grade lymphomas. 57, 58
Maltomas are usually very slowly progressive, but they
sometimes undergo high-grade transformation to
diffuse large-cell B cell lymphomas. They have
mutations consistent with oxidative damage and are
more commonly associated with cag+ H. pylori strain
infection and a more inflamed stomach. High-grade
lymphomas rarely regress following H. pylori treatment.
Recently, a subgroup of  low-grade B cell MALT
lymphomas (approximately 25%) have been found to
have a translocation from chromosome 11 to 1859 This
causes a specific fusion between the activator protein-
12 (AP-12) and MALT-1 genes that creates a new
gene60  whose product stimulates NFêB signaling61. This
is known to be anti-apoptotic and so promotes cell
survival. T(11;18)+ lymphomas are relatively locally
invasive but rarely undergo high-grade transformation;
most importantly, they are unresponsive to H.pylori
treatment.
Gastro-esophageal Reflux and its Complications
Epidemiological observations support a link between
H. pylori and protection against severe GERD and
attendant complications- Barrett’s esophagus (intestinal
metaplasia in the esophagus), and esophageal
adenocarcinoma. If the negative association between
H. pylori and GERD complications is causal, the most
likely mechanism is through effects of H. pylori on
gastric acid secretion. Although some H. pylori–infected
individuals have increased acid secretion, a reduction
is more common, and thus, at a population level,
absence of H. pylori should lead to higher mean acid
secretion. A case control study nested in a cohort
established in 1964 has shown that H. pylori–positive
subjects are less likely than H. pylori–negative subjects
to develop esophageal adenocarcinoma (odds ratio
0.37)62
H. pylori and extragastric diseases.
H. pylori has also been implicated in the pathogenesis
of many extra-gastric diseases, ranging from
atherosclerosis, ischemic heart disease (IHD), liver
diseases, skin diseases, blood disorders, and others,
but documentation is poor and the associations are
controversial. The most convincing data arise in the
field of idiopathic thrombocytopenic purpura (ITP)
and sideropenic anemia. Long-term follow-up studies
have shown that 50% of subjects with ITP maintain a
hematological response after H. pylori eradication.63
CONCLUSION
H. pylori represents one of the most successful human
pathogens, inducing severe clinical symptoms only in
a small subset of individuals, thus signifying a highly
balanced degree of co-evolution of H. pylori and
humans. Three main gastric phenotypes have been
identified as possible outcomes of this co-habitation
namely: simple gastritis; duodenal ulcer and the gastric
cancer phenotypes.
H. pylori has also been implicated in the pathogenesis
of many extragastric diseases which, although
interesting and potentially important, their causality are
yet unproven.
Cytokine gene polymorphisms directly influence inter-
individual variation in the magnitude of cytokine
response, and this clearly contributes to an individual’s
ultimate clinical outcome
Functional genomics may fill many of the gaps in our
understanding of the pathogenesis of H. pylori infection
and accelerate the development of novel therapies,
including H. pylori–specific antimicrobial agents.
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